Partnerships & Alliances
Filter News
Found 55,683 articles
-
PRECISIO BIOTIX THERAPEUTICS ANNOUNCES COLLABORATION WITH MAYO CLINIC
3/14/2024
Precisio Biotix Therapeutics ("Precisio") today announced it has entered into an agreement with Mayo Clinic.
-
QT Imaging’s Breast Acoustic CT™ Scanner Used in Study for Early Identification of Response of Breast Cancer Patients to Neoadjuvant Chemotherapy
3/14/2024
QT Imaging Holdings, Inc. is pleased to announce the delivery of a Breast Acoustic CT™ Scanner under a unique collaboration with the Department of Radiation Oncology, and Radiation Treatment Program at the Sunnybrook Health Sciences Centre in Toronto, Canada.
-
UC Berkeley Launches New Molecular Therapeutics Initiative to Accelerate Drug Discovery
3/14/2024
The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.
-
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
3/14/2024
Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc. today announced an AAV9 production program agreement.
-
Bayer and Aignostics to collaborate on next generation precision oncology
3/14/2024
Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence -powered approaches with applications in precision oncology drug research and development.
-
List Biotherapeutics and Sacco System Announce Lead Share Agreement
3/14/2024
List Biotherapeutics, Inc. and Sacco System Australia Pty Ltd announced a lead share agreement to introduce and mutually recommend each other's microbial development and manufacturing services to prospective customers if one party discovers a project that is better suited to the other party's capability or capacity.
-
Allogene Therapeutics and Arbor Biotechnologies will use their allogeneic CAR T and next-generation gene-editing platforms to develop novel off-the-shelf CAR-T therapies for autoimmune diseases.
-
Expert Systems Celebrates a Milestone with Eilean Therapeutics: Initiation of First-in-Patient Trial of Balamenib, a Selective Best-in-Class Menin Inhibitor
3/13/2024
Expert Systems, a leader in AI-enabled drug discovery, proudly announces a significant milestone in partnership with Eilean Therapeutics LLC: the start of Phase 1 trial of balamenib (ZE63-0302), a highly selective inhibitor of the menin–KMT2A binding interaction, under the Clinical Trial Notification (CTN) scheme of the Australian Therapeutics Goods Administration (TGA).
-
Prime Therapeutics and Capital Rx Enter Into Transformative Strategic Alliance
3/13/2024
Prime Therapeutics LLC/Magellan Rx Management, LLC (Prime), a leading pharmacy solutions organization, and Capital Rx, Inc. (Capital Rx), a renowned health care technology solutions provider, are announcing a strategic alliance.
-
Jasper Health and The Leukemia & Lymphoma Society® (LLS) Collaborate to Support Blood Cancer Patients
3/13/2024
Jasper Health is proud to announce a strategic collaboration with The Leukemia & Lymphoma Society (LLS), a global leader in the fight against blood cancer.
-
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
3/13/2024
The Max Foundation and BeiGene today announced that the first doses of BRUKINSA® (zanubrutinib) have been administered for the treatment of adult patients with chronic lymphocytic leukemia (CLL) to patients in Armenia and Nepal, as part of a three-year collaboration to provide access to the medicine in 29 low- and middle-income countries (LMICs).
-
Children's Mercy Kansas City and Geneyx Inc. Announce Collaboration to Advance Genomic Research and Analysis
3/13/2024
Children's Mercy Kansas City, one of the leading independent pediatric health organizations, and Geneyx Inc. are pleased to announce a collaboration aimed at advancing genomic research and analysis.
-
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
3/13/2024
Almirall, S.A. and Eloxx Pharmaceuticals, Inc. announced that the companies have entered into an exclusive license agreement for the asset ZKN-013.
-
Fabric Genomics Partners with Intermountain Children’s Health to Enhance Precision Diagnosis of Infants and Children Using Whole Genome Sequencing from Broad Clinical Labs
3/13/2024
Fabric Genomics is announcing a new partnership with Intermountain Children’s Health to analyze the whole genomes of children sequenced by the Broad Clinical Labs to help speed diagnosis of kids who may have genetic diseases.
-
Synthetic biology company Pearl Bio announced Tuesday it has entered into a license and collaboration agreement with Merck to discover biologic therapies comprising non-standard amino acids.
-
Bristol Myers Squibb has pulled the plug on a more potent version of its cancer immunotherapy Yervoy. However, the two companies will continue to work on other collaborative programs for T-cell engagers.
-
Pearl Bio Inks Collaboration with Merck to Discover Novel Engineered Biologics
3/12/2024
Pearl Bio today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.
-
Expert Systems Expands Partnership with Eilean Therapeutics and Joins Its Best-in-Class PTPN2 Inhibitor Program
3/12/2024
Expert Systems, a leader in AI-enabled drug discovery, announces the expansion of the collaboration with Eilean Therapeutics as it joins its new PTPN2 inhibitor program, which Eilean has recently acquired from Ness Therapeutics Inc (Ness) in an all-equity transaction.
-
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
3/12/2024
Allogene Therapeutics, Inc. and Arbor Biotechnologies, Inc. today announced a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s next generation AlloCAR T platform for the treatment of autoimmune disease (AID).
-
GV20 Therapeutics Joins NVIDIA Inception to Develop AI Models for Drug and Target Discovery
3/12/2024
GV20 Therapeutics announced today that it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.